After a booming year in 2018, Wuxi has yet to slow down. The following article analyzes the success of Wuxi and its shortcomings.
China has released a number of new policies to help make the biopharma industry more transparent and efficient.
By 2020, China had full coverage of medical service systems in rural and urban areas; 90% of residents in China can...
In the short term, price if dbreak below $160, we will look to buy at 130-140.
As price of Wuxi Apptec with strong support at 130-140.
So long if this level does not fall, we would expect it to regain 200-210 region with a final target at $250
